{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:21:08Z","timestamp":1790688068939,"version":"4.1.0"},"reference-count":22,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"Merck Sharp and Dohme"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.2217\/fmb.15.129","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T11:48:54Z","timestamp":1450352934000},"page":"11-15","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Antifungal Prophylaxis: Why, What and How?"],"prefix":"10.1080","volume":"11","author":[{"given":"Sue","family":"Lyon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/522189"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012054"},{"key":"e_1_3_2_4_1","first-page":"986","article-title":"Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989\u20132003)","volume":"91","author":"Chamilos G","year":"2006","unstructured":"Chamilos G , LunaM, LewisREet al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989\u20132003). Haematologica91, 986\u2013989 (2006).","journal-title":"Haematologica"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_2_6_1","volume-title":"41st Annual Meeting of the European Society for Blood and Marrow (EBMT)","author":"Vega HDR","year":"2015","unstructured":"Vega HDR , ScocorroCF, GuerolaBT, NavarroJMF. Invasive fungal infection in pediatric hematopoietic stem cell transplantation, Abstract P268. Presented at: 41st Annual Meeting of the European Society for Blood and Marrow (EBMT). Istanbul, Turkey, 22\u201325 March 2015."},{"key":"e_1_3_2_7_1","volume-title":"41st Annual Meeting of the European Society for Blood and Marrow Transplantation","author":"Acevedo CC","year":"2015","unstructured":"Acevedo CC , PoyatoMJL, TorresEGet al. Voriconazole as antifungal prophylaxis in allogeneic hematopoietic stem cell transplantation: ten years of experience in a single institution, Abstract PO25. Presented at: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. Istanbul, Turkey, 22\u201325 March 2015."},{"key":"e_1_3_2_8_1","volume-title":"European Conference on Infections in Leukaemia (ECIL)","author":"Herbrecht R","year":"2013","unstructured":"Herbrecht R . 2013 \u2013 update of the ECIL guidelines for antifungal therapy in leukaemia and HSCT patients (ECIL-5). Presented at: European Conference on Infections in Leukaemia (ECIL). Sophia Antipolis, France, 19\u201321 September 2013. www.kobe.fr\/ecil\/telechargements2013\/ECIL5%20Antifungal%20Therapy.pdf."},{"key":"e_1_3_2_9_1","volume-title":"European Conference on Infections in Leukaemia (ECIL)","author":"Maertens J","year":"2013","unstructured":"Maertens J . Primary antifungal prophylaxis. Presented at: European Conference on Infections in Leukaemia (ECIL). Sophia Antipolis, France, 19\u201321 September 2013. www.kobe.fr\/ecil\/telechargements2013\/ECIL5antifungalprophylaxis%2020062014Final.pdf."},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268151"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08838.x"},{"key":"e_1_3_2_12_1","volume-title":"Infectious Diseases Week","author":"Kontoyiannis D","year":"2014","unstructured":"Kontoyiannis D , GiladiM, LeeMet al. A Phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in invasive aspergillosis patients, Abstract 1211. Presented at: Infectious Diseases Week. Philadelphia, PA, USA, 8\u201312 October 2014."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04569-14"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis773"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1328"},{"key":"e_1_3_2_16_1","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) . Assessment report: Noxafil (international non-proprietary name: posaconazole). EMA\/159150\/201420February 2014."},{"key":"e_1_3_2_17_1","unstructured":"FDA . Clinical review. Posaconazole delayed release tablets. 6 March 2009."},{"key":"e_1_3_2_18_1","volume-title":"European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","author":"Cornely OA","year":"2013","unstructured":"Cornely OA , DuarteRF, HaiderSet al. Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) tablet in patients at risk for invasive fungal infection. Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Berlin, Germany, 27\u201330 April 2013."},{"key":"e_1_3_2_19_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Cornely OA","year":"2013","unstructured":"Cornely OA , HaiderS, GriggAet al. Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) IV in patients (Pts) at risk for invasive fungal infection (IFI), Abstract A-292. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC, USA, 5\u20139 September 2013."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04035-14"},{"key":"e_1_3_2_21_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Jancel T","year":"2014","unstructured":"Jancel T , KumarP, MalechHLet al. Posaconazole serum concentrations of the delayed-release tablets compared with the oral suspension, Abstract A-703. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC, USA, 5\u20139 September 2014."},{"key":"e_1_3_2_22_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Miceli MH","year":"2014","unstructured":"Miceli MH , PerissinottiAJ, KaufmanCet al. Clinical experience using posaconazole (pos) extended release tablet (tab) for the prevention of invasive fungal infections in haematological cancer patients (pt): does one size fit all? Abstract M-1759. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC, USA, 5\u20139 September 2014."},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.3851"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb.15.129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:54Z","timestamp":1719124734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb.15.129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,17]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.2217\/fmb.15.129"],"URL":"https:\/\/doi.org\/10.2217\/fmb.15.129","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}